Is red meat intake a risk factor for breast cancer among premenopausal women? Valerie H. TaylorMonali MisraSom D. Mukherjee Review 20 June 2009 Pages: 1 - 8
Vitreo-retinal traction and anastrozole use Alvin EisnerEmily J. ThielmanJohn T. Vetto Preclinical Study 20 August 2008 Pages: 9 - 16
Genomic instability demonstrates similarity between DCIS and invasive carcinomas Christopher M. HeaphyMarco BisoffiJeffrey K. Griffith Preclinical study 11 September 2008 Pages: 17 - 24
When genomic and standard test results diverge: implications for breast cancer patients’ preference for chemotherapy Noel T. BrewerAlrick S. EdwardsBarbara K. Rimer Preclinical Study 11 September 2008 Pages: 25 - 29
TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro Rebecca L. H. BigelowBriana J. WilliamsJames A. Cardelli Preclinical Study 12 September 2008 Pages: 31 - 44
Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo Rui WangXi WangHui-Zhong Zhang Preclinical Study 13 September 2008 Pages: 45 - 54
BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer Weiqiu ChenKaifeng PanYuntao Xie Preclinical Trial 30 May 2008 Pages: 55 - 60
Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow Anthony LucciSavitri KrishnamurthyMassimo Cristofanilli Clinical Trial 29 July 2008 Pages: 61 - 68
Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial Louis MauriacGilles RomieuJosé Bines Clinical Trial 23 November 2008 Pages: 69 - 75
Prospective assessment of the endometrium in postmenopausal breast cancer patients treated with fulvestrant Leilani MoralesPatrick NevenRobert Paridaens Clinical Trial 02 December 2008 Pages: 77 - 81
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab Aruna ManiJulie RodaCharles L. Shapiro Clinical Trial 03 December 2008 Pages: 83 - 89
Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer James MansellIan J. MonypennyJulie C. Doughty Clinical Trial 27 December 2008 Pages: 91 - 98
Comparing patients’ and clinicians’ assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial) Michaella J. SmithP. Grantley GillThe Royal Australasian College of Surgeons SNAC Trial Group Epidemiology 17 October 2008 Pages: 99 - 109
Breast cancer survivors who use estrogenic botanical supplements have lower serum estrogen levels than non users Sharon J. WayneMarian L. NeuhouserRachel Ballard-Barbash Epidemiology 18 October 2008 Pages: 111 - 119
Analysis of the effect of age on the prognosis of breast cancer C. CluzeM. ColonnaN. Bossard Epidemiology 18 October 2008 Pages: 121 - 129
High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1 Biyun QianDionyssios KatsarosHerbert Yu Epidemiology 19 October 2008 Pages: 131 - 140
Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis Ya-shuang ZhaoSui ZhuXia Li Epidemiology 02 November 2008 Pages: 141 - 150
Low penetrance breast cancer predisposition SNPs are site specific Niall McinerneyGabrielle ColleranElinor Sawyer Epidemiology 13 November 2008 Pages: 151 - 159
Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk Pablo Serrano-FernándezTadeusz DębniakJan Lubiński Epidemiology 22 November 2008 Pages: 161 - 165
Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry Ellen T. ChangRoger L. MilneEsther M. John Epidemiology 26 November 2008 Pages: 167 - 176
Single frequency versus bioimpedance spectroscopy for the assessment of lymphedema S. L. YorkL. C. WardS. L. Kilbreath Brief Report 18 June 2008 Pages: 177 - 182
Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors Anita L. BaneDushanthi PinnaduwageIrene L. Andrulis Brief Report Open access 18 June 2008 Pages: 183 - 191
Lobular involution: localized phenomenon or field effect? Robert A. VierkantLynn C. HartmannCarol A. Reynolds Brief Report 01 July 2008 Pages: 193 - 196
Vitiligo in the affected breast during neo-adjuvant chemotherapy for breast cancer Maithili V. RaoMichelle Shayne Brief Report 01 July 2008 Pages: 197 - 198
Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status William D. FoulkesMatthew J. GraingeIan O. Ellis Brief Report 04 July 2008 Pages: 199 - 204
Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer Marjorie ZaudererSujata PatilArti Hurria Brief Report 13 July 2008 Pages: 205 - 210
Lack of prognostic significance of “classic” lobular breast carcinoma: a matched, single institution series Giuseppe VialeNicole RotmenszAlan S. Coates Report 16 July 2008 Pages: 211 - 214
Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156_157insAlu Ana PeixotoCatarina SantosManuel R. Teixeira Letter to the editor 14 October 2008 Pages: 215 - 217
MCF-7 breast carcinoma cells do not express caspase-3 Reiner U. Jänicke Letter to the editor 14 October 2008 Pages: 219 - 221
Sustained lower rates of breast cancer in the United States Kathleen A. CroninPeter M. RavdinBrenda K. Edwards Letter to the Editor 01 November 2008 Pages: 223 - 224
UGT2B7 is not expressed in normal breast Chang SunAnna Di Rienzo Letter to the Editor 31 December 2008 Pages: 225 - 226
